Skip to main content
Erschienen in: Angiogenesis 1/2018

09.10.2017 | Original Paper

Antiangiogenesis and medical therapy failure in intracranial atherosclerosis

verfasst von: Nestor R. Gonzalez, Raymond Liou, Florian Kurth, Hao Jiang, Jeffrey Saver

Erschienen in: Angiogenesis | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Intracranial atherosclerotic disease (ICAD) is one of the most common causes of stroke worldwide and the one with the worst prognosis. In this study, we assessed the hypothesis that the balance of circulating pro- and antiangiogenic factors plays a role in the evolution of the disease and can be used as a potential marker for the disease course and a target for treatment. Seventy-four patients with severe ICAD were enrolled in this prospective observational study, medically optimized, and followed for 6 months. Thirteen pro- and eight antiangiogenic factors were measured in the participants’ serum using a sandwich multiplex ELISA. Angiogenic profiles were calculated using principal component analysis. We tested the association between angiogenic profiles and recurring cerebrovascular events despite intensive medical therapy, disability at 6 months after enrollment, and angiographic neovascularization in patients who failed medical treatment and underwent indirect revascularization surgery. There is a strong association between a functionally antiangiogenic profile and recurrent stroke or TIA in patients with ICAD (OR = 7.2, CI 2.4–34.4). Multivariable regression analysis showed that this antiangiogenic profile was also associated with poor functional status after 6 months (p = 0.002), independent from other clinical features such as history of previous stroke, diabetes, and age. In patients who failed medical management and underwent indirect revascularization surgery, high endostatin and angiostatin levels were also associated with low angiographic neovascularization (p = 0.02). The results of this study point to the striking importance of antiangiogenesis as a determinant of ICAD patient prognosis and suggest a possible new target for therapy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Gorelick PB, Wong KS, Bae H-J, Pandey DK (2008) Large artery intracranial occlusive disease a large worldwide burden but a relatively neglected frontier. Stroke 39(8):2396–2399CrossRefPubMed Gorelick PB, Wong KS, Bae H-J, Pandey DK (2008) Large artery intracranial occlusive disease a large worldwide burden but a relatively neglected frontier. Stroke 39(8):2396–2399CrossRefPubMed
2.
Zurück zum Zitat De Silva DA, Woon F-P, Lee M-P, Chen CP, Chang H-M, Wong M-C (2007) South Asian patients with ischemic stroke intracranial large arteries are the predominant site of disease. Stroke 38(9):2592–2594CrossRefPubMed De Silva DA, Woon F-P, Lee M-P, Chen CP, Chang H-M, Wong M-C (2007) South Asian patients with ischemic stroke intracranial large arteries are the predominant site of disease. Stroke 38(9):2592–2594CrossRefPubMed
3.
4.
Zurück zum Zitat Sacco RL, Kargman D, Gu Q, Zamanillo M (1995) Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study. Stroke 26(1):14–20CrossRefPubMed Sacco RL, Kargman D, Gu Q, Zamanillo M (1995) Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study. Stroke 26(1):14–20CrossRefPubMed
5.
Zurück zum Zitat Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL (2014) Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 383(9914):333–341CrossRefPubMed Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL (2014) Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 383(9914):333–341CrossRefPubMed
6.
Zurück zum Zitat Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG (2005) Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352(13):1305-1316. doi:352/13/1305 [pii] 10.1056/NEJMoa043033 Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG (2005) Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352(13):1305-1316. doi:352/13/1305 [pii] 10.​1056/​NEJMoa043033
7.
Zurück zum Zitat Wityk R, Lehman D, Klag M, Coresh J, Ahn H, Litt B (1996) Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 27(11):1974CrossRefPubMed Wityk R, Lehman D, Klag M, Coresh J, Ahn H, Litt B (1996) Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 27(11):1974CrossRefPubMed
8.
Zurück zum Zitat Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF (2011) Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 365:993–1003CrossRefPubMedPubMedCentral Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF (2011) Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 365:993–1003CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Awad I, Furlan AJ, Little JR (1984) Changes in intracranial stenotic lesions after extracranial-intracranial bypass surgery. J Neurosurg 60(4):771–776CrossRefPubMed Awad I, Furlan AJ, Little JR (1984) Changes in intracranial stenotic lesions after extracranial-intracranial bypass surgery. J Neurosurg 60(4):771–776CrossRefPubMed
10.
Zurück zum Zitat Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP (2011) Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia. JAMA, J Am Med Assoc 306(18):1983–1992CrossRef Powers WJ, Clarke WR, Grubb RL Jr, Videen TO, Adams HP Jr, Derdeyn CP (2011) Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia. JAMA, J Am Med Assoc 306(18):1983–1992CrossRef
11.
Zurück zum Zitat Arenillas JF, Alvarez-Sabin J, Montaner J, Rosell A, Molina CA, Rovira A, Ribo M, Sanchez E, Quintana M (2005) Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke 36(1):92–97. doi:10.1161/01.STR.0000149617.65372.5d CrossRefPubMed Arenillas JF, Alvarez-Sabin J, Montaner J, Rosell A, Molina CA, Rovira A, Ribo M, Sanchez E, Quintana M (2005) Angiogenesis in symptomatic intracranial atherosclerosis: predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence. Stroke 36(1):92–97. doi:10.​1161/​01.​STR.​0000149617.​65372.​5d CrossRefPubMed
12.
Zurück zum Zitat Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, Penalba A, Boada C, Domingues-Montanari S, Ribo M, Alvarez-Sabin J, Montaner J (2011) A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis 216(1):205–211. doi:10.1016/j.atherosclerosis.2011.01.030 CrossRefPubMed Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, Penalba A, Boada C, Domingues-Montanari S, Ribo M, Alvarez-Sabin J, Montaner J (2011) A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis 216(1):205–211. doi:10.​1016/​j.​atherosclerosis.​2011.​01.​030 CrossRefPubMed
13.
Zurück zum Zitat Massot A, Navarro-Sobrino M, Penalba A, Arenillas JF, Giralt D, Ribo M, Molina CA, Alvarez-Sabin J, Montaner J, Rosell A (2013) Decreased levels of angiogenic growth factors in intracranial atherosclerotic disease despite severity-related increase in endothelial progenitor cell counts. Cerebrovasc Dis 35(1):81–88. doi:10.1159/000346097 CrossRefPubMed Massot A, Navarro-Sobrino M, Penalba A, Arenillas JF, Giralt D, Ribo M, Molina CA, Alvarez-Sabin J, Montaner J, Rosell A (2013) Decreased levels of angiogenic growth factors in intracranial atherosclerotic disease despite severity-related increase in endothelial progenitor cell counts. Cerebrovasc Dis 35(1):81–88. doi:10.​1159/​000346097 CrossRefPubMed
14.
Zurück zum Zitat Gonzalez NR, Dusick JR, Connolly M, Bounni F, Martin NA, Van de Wiele B, Liebeskind DS, Saver JL (2015) Encephaloduroarteriosynangiosis for adult intracranial arterial steno-occlusive disease: long-term single-center experience with 107 operations. J Neurosurg. doi:10.3171/2014.10.JNS141426 Gonzalez NR, Dusick JR, Connolly M, Bounni F, Martin NA, Van de Wiele B, Liebeskind DS, Saver JL (2015) Encephaloduroarteriosynangiosis for adult intracranial arterial steno-occlusive disease: long-term single-center experience with 107 operations. J Neurosurg. doi:10.​3171/​2014.​10.​JNS141426
17.
Zurück zum Zitat Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108(16):1933–1938. doi:10.1161/01.CIR.0000093398.16124.29 CrossRefPubMed Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108(16):1933–1938. doi:10.​1161/​01.​CIR.​0000093398.​16124.​29 CrossRefPubMed
19.
Zurück zum Zitat Rajpathak SN, Wang T, Wassertheil-Smoller S, Strickler HD, Kaplan RC, McGinn AP, Wildman RP, Rosenbaum D, Rohan TE, Scherer PE, Cushman M, Ho GYF (2010) Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the women’s health initiative. Stroke 41(5):857–862. doi:10.1161/strokeaha.109.567719 CrossRefPubMedPubMedCentral Rajpathak SN, Wang T, Wassertheil-Smoller S, Strickler HD, Kaplan RC, McGinn AP, Wildman RP, Rosenbaum D, Rohan TE, Scherer PE, Cushman M, Ho GYF (2010) Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the women’s health initiative. Stroke 41(5):857–862. doi:10.​1161/​strokeaha.​109.​567719 CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Chen XY, Wong KS, Lam WW, Zhao HL, Ng HK (2008) Middle cerebral artery atherosclerosis: histological comparison between plaques associated with and not associated with infarct in a postmortem study. Cerebrovasc Dis 25(1–2):74–80. doi:10.1159/000111525 CrossRefPubMed Chen XY, Wong KS, Lam WW, Zhao HL, Ng HK (2008) Middle cerebral artery atherosclerosis: histological comparison between plaques associated with and not associated with infarct in a postmortem study. Cerebrovasc Dis 25(1–2):74–80. doi:10.​1159/​000111525 CrossRefPubMed
21.
Zurück zum Zitat Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T (1997) HGF/NK4 is a speci¢c antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS J 420:1–6CrossRef Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T (1997) HGF/NK4 is a speci¢c antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS J 420:1–6CrossRef
22.
Zurück zum Zitat Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T (2000) HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60:6737–6743PubMed Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T (2000) HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60:6737–6743PubMed
24.
Zurück zum Zitat Gonzalez NR, Liebeskind DS, Dusick JR, Mayor F, Saver J (2013) Intracranial arterial stenoses: current viewpoints, novel approaches, and surgical perspectives. Neurosurg Rev 36(2):175–184. doi:10.1007/s10143-012-0432-z discussion 184–175 CrossRefPubMed Gonzalez NR, Liebeskind DS, Dusick JR, Mayor F, Saver J (2013) Intracranial arterial stenoses: current viewpoints, novel approaches, and surgical perspectives. Neurosurg Rev 36(2):175–184. doi:10.​1007/​s10143-012-0432-z discussion 184–175 CrossRefPubMed
Metadaten
Titel
Antiangiogenesis and medical therapy failure in intracranial atherosclerosis
verfasst von
Nestor R. Gonzalez
Raymond Liou
Florian Kurth
Hao Jiang
Jeffrey Saver
Publikationsdatum
09.10.2017
Verlag
Springer Netherlands
Erschienen in
Angiogenesis / Ausgabe 1/2018
Print ISSN: 0969-6970
Elektronische ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-017-9578-1

Weitere Artikel der Ausgabe 1/2018

Angiogenesis 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.